Compare FAC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAC | PRLD |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.9M | 529.1M |
| IPO Year | 2025 | 2020 |
| Metric | FAC | PRLD |
|---|---|---|
| Price | $6.30 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.00 | $9.20 |
| AVG Volume (30 Days) | 344.2K | ★ 395.6K |
| Earning Date | 11-15-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $258.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $4.24 | $1.15 |
| 52 Week High | $15.40 | $6.83 |
| Indicator | FAC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 32.49 |
| Support Level | $4.27 | $3.40 |
| Resistance Level | $6.77 | $4.10 |
| Average True Range (ATR) | 0.41 | 0.28 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 73.80 | 11.76 |
Factorial Energy Inc is an American solid-state battery innovator backed by In-Q-Tel - the not-for-profit strategic investor for the U.S. national security community and America's allies - and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST and Solstice platforms, engineered for scalable manufacturing, it delivers industry performance across defense, space, and energy storage applications. Mercedes-Benz's real-world road testing in a lightly modified test vehicle achieved over 1,200 km of range on a single charge, while Stellantis-lab testing verified 77 Ah cells demonstrating high energy density, fast-charging, and robust use for energy and power performance across temperature extremes.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.